Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Age at baseline (median with range) 67 (35–83)
Gender (% females) 36/66 (55%)
Prior systemic therapy:
 None 36
 IL-2 12
 Temozolomide 6
 Radiation therapy/IL-2 1
 Radiation therapy 1
 Temozolomide/Vemorafenib 1
 RT/Temozolomide 1
 IFN/IL-2 6
 Vemorafenib 2
RECIST response
 PD 41
 SD 14
 PR 9
 CR 2
Lactate dehydrogenase (LDH)
 > = 250 IU/L 12
 < 250 IU/L 53
  1. PD Progressive disease, SD Stable disease, PR Partial response, CR Complete response